Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
ViiV Healthcare announces US regulatory submission for a single-tablet regimen combining dolutegravir with abacavir and lamivudine

In Europe, a Marketing Authorisation Application (MAA) for this single-tablet regimen will be submitted in the near future. The review of the MAA for dolutegravir (DTG), submitted in Europe in December 2012, is in progress with the European Medicines Agency (EMA).

Published
23 October 2013
From
Viiv Healthcare
HIV Dual Therapy Matches Standard Triple Cocktail

A two-drug regimen (lopinavir/ritonavir plus lamivudine) for HIV did as well in controlling the virus as a standard triple-drug cocktail, researchers found. After 48 weeks of therapy with the dual-drug regimen, 88.3% of patients had undetectable virus.

Published
19 October 2013
From
MedPage Today
MODERN Study Stopped: An NRTI-Sparing, Two-Drug Initial Regimen Disappoints Again

In case you didn’t know, “MODERN” is the clever name for the “Maraviroc Once-daily with Darunavir Enhanced by Ritonavir in a New regimen” trial, which compared TDF/FTC to maraviroc, both with boosted darunavir. And once again, the NRTI-sparing two-drug regimen comes up short.

Published
17 October 2013
From
NEJM Journal Watch
Elusive secret of HIV long-term immunity

Scientists have discovered a critical new clue about why some people are able to control the HIV virus long term without taking antiviral drugs. These rare individuals who do not require medicine have an extra helping of a certain type of immune protein that blocks HIV from spreading within the body.

Published
17 October 2013
From
EurekAlert!
Merck plans phase III study of once-daily raltegravir (Isentress)

The poster presentation A Single Dose Food Effect Study of Raltegravir Formulations (Poster #PE10/17) will be presented Thursday, Oct. 17, and Friday, Oct. 18, from 12:00 p.m. to 2:00 p.m. CET. Based on the results of this study and other data, Merck plans to initiate a Phase III clinical study on a once daily dosing regimen of ISENTRESS in early 2014, pending review by regulatory agencies. ISENTRESS is administered twice daily, in accordance with the approved Prescribing Information.

Published
16 October 2013
From
Merck press release
Janssen seeks European marketing approval for combination of once-daily darunavir with cobicistat

Janssen-Cilag International NV (Janssen), today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for a once-daily single tablet fixed-dose antiretroviral combination product containing darunavir, a protease inhibitor developed by Janssen, with cobicistat, a pharmacokinetic enhancer or boosting agent, developed by Gilead Sciences, Inc. (Gilead) for use in combination with other human immunodeficiency virus (HIV-1) medicines.

Published
15 October 2013
From
News Medical Net
Viriom Reports Clinical Efficacy Data for VM-1500, a New HIV NNRTI

Dr. Vadim Bichko, Chief Scientific Officer of Viriom, presented positive interim results for a phase Ib/IIa study with VM-1500, a new HIV NNRTI (non-nucleoside reverse transcriptase inhibitor), at the 15th Annual International Meeting of the Institute of Human Virology (held September 8-11, 2013, in Moscow, Russia).

Published
08 October 2013
From
Marketwired (press release)
Gladstone lab uncovers a potential HIV cure — and it's already a drug

Monkeys' evolutionary protection against a virus similar to HIV may be mimicked by a drug sitting on a biotech company's shelf, says a Gladstone Institutes researcher who wants to take the drug into clinical trials

Published
06 October 2013
From
San Francisco Business Times
Long-Acting HIV Antiretrovirals May Be Revolutionary. But Will They Be Worth It?

Once-a-month HIV antiretroviral dosing is no longer a fanciful dream. Long-acting antiretrovirals are currently in development, and the first glimpses of early safety/efficacy data are not terribly far away. So it's not outlandish for us to start thinking about where these drugs might fit into the HIV treatment armamentarium once they arrive. But will they be cost-effective?

Published
06 October 2013
From
The Body Pro
From sky high to CHAI – what needs to be done about dolutegravir pricing?

With a low 50 mg once-daily dose, good efficacy, minimal toxicity, pregnancy category B, and the potential to be low cost and co-formulated, dolutegravir is an attractive contender for use in low- and middle-income countries.

Published
02 October 2013
From
HIV I-Base

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.